TSHA Share Price Performance
US$4.94
2.97 (150.76%)
48.0% undervalued intrinsic discount
US$9.50
Fair Value
Price US$4.94
AnalystConsensusTarget US$9.50
Fair ValueUS$9.50
Share PriceUS$4.94
48.0% undervalued intrinsic discount
Taysha Gene Therapies, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
TSHA Community Narratives
AN
Fair Value US$9.5 48.0% undervalued intrinsic discount
FDA Meetings And TSHA-102 Trials Will Advance Approval
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
FDA Meetings And TSHA-102 Trials Will Advance Approval
Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
US$9.5
48.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
126.33% p.a.
Profit Margin
16.43%
Future PE
251.2x
Share price in 2028
US$11.6
Snowflake Analysis
Taysha Gene Therapies, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.34
- 100.00%
- -1,144.97%
- 16.5%
About TSHA
- Founded
- 2019
- Employees
- 73
- CEO
- WebsiteView website
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
